Requests that the FDA declare that the proposed drug product, Apixaban orally di sintegrating tablets 2.5 mg and 5 mg is suitable for submission as an ANDA. The listed reference drug product (RLD), upon which this petition is based, is ELIQUIS® (apixaban) Tablets, 2.5 mg and 5 mg, by Bristol-Myers Squibb, NDA #202155
🏛 Food and Drug Administration (FDA)FDA-2026-P-4800
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.